AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22703550 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary HIV counselling and testing (VCT)
Number of subjects: 6778
Study 22703550 — intervention group
Group type: EXPERIMENTAL
Intervention: No stigmatizing attitudes toward people living with HIV/AIDS
Number of subjects: 6778
Study 22703550 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger men (aged ≤44 years) and those of higher socio-economic position (SEP) in rural areas
Number of subjects: 6778
Study 22703550 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky sexual behaviour among urban men
Number of subjects: 6778
Study 22703550 — intervention group
Group type: EXPERIMENTAL
Intervention: Being Muslim
Number of subjects: 6778
Study 22703550 — intervention group
Group type: EXPERIMENTAL
Intervention: Area of residence and socio-economic position (SEP)
Number of subjects: 6778
Study 20042981 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant reports on Economic indicators
Number of subjects: 97
Study 20042981 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant reports on Community indicators
Number of subjects: 97
Study 20042981 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant reports on Social indicators
Number of subjects: 97
Study 20042981 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant reports on Satisfaction items
Number of subjects: 97
Study 20042981 — intervention group
Group type: COMPARATOR
Intervention: Significant others' self-reported degree of awareness of participants' concerns
Number of subjects: 97
Study 20042981 — intervention group
Group type: COMPARATOR
Intervention: Severity of TBI
Number of subjects: 97
Study 18816381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall prevention programme
Number of subjects: 166
Study 15983288 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.8 mg/d)
Number of subjects: 530
Study 15983288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 11999911 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH test
Number of subjects: 58
Study 11999911 — intervention group
Group type: EXPERIMENTAL
Intervention: DST
Number of subjects: 58
Study 10372975 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 8
Study 10372975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (850 mmol L(‐1))
Number of subjects: 8
Study 10372975 — intervention group
Group type: COMPARATOR
Intervention: Time control (no saline infusion)
Number of subjects: 8
Study 8826919 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study 8826919 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography (excluding Canadian National Breast Screening Study results)
Number of subjects: 0
Study 2350441 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine with a high-fat meal
Number of subjects: 8
Study 2350441 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine without a high-fat meal
Number of subjects: 8
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (1 dose)
Number of subjects: 40000
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (2 doses)
Number of subjects: 40000
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (3 doses)
Number of subjects: 40000
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (4 doses)
Number of subjects: 40000
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (1 dose annually for 3 years)
Number of subjects: 40000
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (2 doses in the first year followed by annual reimmunizations)
Number of subjects: 40000
Study 4539414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine (after 4 doses)
Number of subjects: 40000
Study 31039753 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component pregnancy lifestyle intervention (adapted from the Diabetes Prevention Program)
Number of subjects: 400
Study 31039753 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 400
Study 28699559 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering water containers
Number of subjects: 11995
Study 28699559 — intervention group
Group type: EXPERIMENTAL
Intervention: Temephos application in water containers
Number of subjects: 11995
Study 28699559 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of temephos (in urban areas)
Number of subjects: 11995
Study 28699559 — intervention group
Group type: COMPARATOR
Intervention: Having more than four water containers
Number of subjects: 11995
Study 28699559 — intervention group
Group type: COMPARATOR
Intervention: Low education of the household head
Number of subjects: 11995
Study 28699559 — intervention group
Group type: COMPARATOR
Intervention: Household head without paid work (in rural areas)
Number of subjects: 11995
Study 28699559 — intervention group
Group type: COMPARATOR
Intervention: Being in the Acapulco region (in rural areas)
Number of subjects: 11995
Study 28699559 — intervention group
Group type: COMPARATOR
Intervention: Using anti-mosquito products (in rural areas)
Number of subjects: 11995
Study 25728846 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of the EVEREST trial
Number of subjects: 1907
Study 24377216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (shu‐stream point acupuncture combined with fire needle therapy)
Number of subjects: 80
Study 24377216 — intervention group
Group type: COMPARATOR
Intervention: Medication group (votalin emulgel)
Number of subjects: 80
Study 21490974 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalysts
Number of subjects: 14
Study 21490974 — intervention group
Group type: COMPARATOR
Intervention: Medical students, oncologists, cognitive behavioral therapists, individuals with the same history of sibling's cancer
Number of subjects: 14
Study 19371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up
Number of subjects: 36
Study 19371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 36
Study 19371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 36
Study 19371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up and static stretching
Number of subjects: 36
Study 19371432 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 36
Study 19371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up and static stretching response
Number of subjects: 36
Study 16675058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling retraining (GI)
Number of subjects: 47
Study 16675058 — intervention group
Group type: EXPERIMENTAL
Intervention: Running retraining (GII)
Number of subjects: 47
Study 16675058 — intervention group
Group type: COMPARATOR
Intervention: Control group (GIII)
Number of subjects: 47
Study 15297895 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery relaxation
Number of subjects: 26
Study 15297895 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest quietly)
Number of subjects: 26
Study 11738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (2 oral 500 mg doses at 12-hour intervals)
Number of subjects: 42
Study 11738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (single oral 500 mg dose)
Number of subjects: 42
Study 11738912 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (single oral 400 mg dose)
Number of subjects: 42
Study 8996152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin as an adjunct to radiation therapy
Number of subjects: 203
Study 8996152 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 203
Study 8214177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (8 sessions)
Number of subjects: 68
Study 8214177 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support group therapy (8 sessions)
Number of subjects: 68
Study 8214177 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 68
Study 3677279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.4 ml.kg‐1)
Number of subjects: 25
Study 3677279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 29073815 — intervention group
Group type: EXPERIMENTAL
Intervention: MeroGel (Group 1, n=72)
Number of subjects: 205
Study 29073815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage (Group 2, n=64)
Number of subjects: 205
Study 29073815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MeroGel and cartilage (Group 3, n=69)
Number of subjects: 205
Study 27716128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Treatment (TT)
Number of subjects: 120
Study 27716128 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Tailored Treatment (NTT)
Number of subjects: 120
Study 27716128 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 120
Study 24534128 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide plus rt-PA (0.6 mg/kg rt-PA, 135 mcg/kg bolus, 0.75 mcg/kg/min two-hour infusion)
Number of subjects: 54
Study 24534128 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide plus rt-PA
Number of subjects: 54
Study 24534128 — intervention group
Group type: COMPARATOR
Intervention: rt-PA alone (0.9 mg/kg)
Number of subjects: 54
Study 24534128 — intervention group
Group type: COMPARATOR
Intervention: rt-PA alone
Number of subjects: 54
Study 23740905 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based education course
Number of subjects: 0
Study 23740905 — intervention group
Group type: COMPARATOR
Intervention: Facilitators' abilities
Number of subjects: 0
Study 23740905 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall impact of the course
Number of subjects: 0
Study 20613484 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (5, 10, 15, 20, 30, or 40 mg)
Number of subjects: 300
Study 20613484 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (7, 15, 20, 30, 45, or 60 mg)
Number of subjects: 300
Study 18756037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Number of subjects: 59
Study 18756037 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Number of subjects: 59
Study 16738029 — intervention group
Group type: EXPERIMENTAL
Intervention: High ranking competitors (e.g., #2 vs. #3)
Number of subjects: 8
Study 16738029 — intervention group
Group type: COMPARATOR
Intervention: Low ranking competitors (e.g., #202 vs. #203)
Number of subjects: 8
Study 16738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to meaningful standards (e.g., bottom of a ranking scale or qualitative threshold)
Number of subjects: 8
Study 16738029 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological processes related to proximity to a standard
Number of subjects: 8
Study 15478158 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom leather splint
Number of subjects: 45
Study 15478158 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolyan commercial splint
Number of subjects: 45
Study 15478158 — intervention group
Group type: COMPARATOR
Intervention: Anatech commercial splint
Number of subjects: 45
Study 15478158 — intervention group
Group type: EXPERIMENTAL
Intervention: All splints
Number of subjects: 45
Study 15478158 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist splints (overall)
Number of subjects: 45
Study 11731729 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 0.2 mg/kg
Number of subjects: 27
Study 11731729 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil 25 mg
Number of subjects: 27
Study 11731729 — intervention group
Group type: COMPARATOR
Intervention: no drug
Number of subjects: 27
Study 9256187 — intervention group
Group type: EXPERIMENTAL
Intervention: T10B9
Number of subjects: 81
Study 9256187 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 81
Study 9256187 — intervention group
Group type: COMPARATOR
Intervention: Both mAbs
Number of subjects: 81
Study 8098919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation (5 s, 50 Hz, 60 mA)
Number of subjects: 22
Study 2956872 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (150 mg, 3 times daily)
Number of subjects: 13
Study 2956872 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg, 3 times daily)
Number of subjects: 13
Study 2956872 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapy with diuretics)
Number of subjects: 13
Study 31790144 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist ganirelix
Number of subjects: 40
Study 31790144 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (steroidogenic inhibitor)
Number of subjects: 40
Study 31790144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ganirelix and repeated LH infusions
Number of subjects: 40
Study 30500903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling (four times during pregnancy)
Number of subjects: 378
Study 30500903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle counselling)
Number of subjects: 378
Study 30500903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Number of subjects: 378
Study 30500903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 378
Study 28129251 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 41
Study 28129251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary π-GST
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urine Hepcidin:Creatine ratio at 24h
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater urine NGAL:Cr ratio post-op
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater serum CysC at 24h
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin:Cr 24h + post-operative π-GST
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin:Cr 24h + NGAL:Cr post-op
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC 24h + post-operative π-GST
Number of subjects: 93
Study 25585949 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL:Cr measurement post-op followed by Hepcidin:Cr at 24h
Number of subjects: 93
Study 23719397 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces with lesions
Number of subjects: 45
Study 23719397 — intervention group
Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 45
Study 21350054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1817
Study 21350054 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 1817
Study 19057210 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors (sildenafil, vardenafil, tadalafil)
Number of subjects: 0
Study 17407176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Number of subjects: 1059
Study 15366391 — intervention group
Group type: EXPERIMENTAL
Intervention: Recycled stainless steel brackets
Number of subjects: 20
Study 15366391 — intervention group
Group type: COMPARATOR
Intervention: New stainless steel brackets
Number of subjects: 20
Study 11463545 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 10% (200;0.5) colloid prime
Number of subjects: 20
Study 11463545 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid prime (Ringer's lactate)
Number of subjects: 20
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT (omeprazole 20 mg q.d.s. + clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: OC (omeprazole 20 mg o.d. + clarithromycin 250 mg b.d.)
Number of subjects: 128
Study 9663723 — intervention group
Group type: COMPARATOR
Intervention: C (clarithromycin 250 mg b.d.)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT (in patients with pre-treatment metronidazole resistance)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (in patients with pre-treatment metronidazole resistance)
Number of subjects: 128
Study 9663723 — intervention group
Group type: COMPARATOR
Intervention: C (post-treatment resistance to clarithromycin)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: OC (post-treatment resistance to clarithromycin)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (post-treatment resistance to both antibiotics)
Number of subjects: 128
Study 9663723 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT (post-treatment resistance to both antibiotics)
Number of subjects: 128
Study 7933844 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant infusion method
Number of subjects: 14
Study 7933844 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection technique
Number of subjects: 14
Study 7933844 — intervention group
Group type: COMPARATOR
Intervention: Urinary clearance of inulin
Number of subjects: 14
Study 3224003 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Component Program
Number of subjects: 402
Study 3224003 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Program
Number of subjects: 402
Study 3224003 — intervention group
Group type: EXPERIMENTAL
Intervention: American Cancer Society Quitter's Guide
Number of subjects: 402
Study 3224003 — intervention group
Group type: COMPARATOR
Intervention: Usual spontaneous quit rate
Number of subjects: 402
Study 3224003 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall long-term quit rates
Number of subjects: 402
Study 29642115 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR)
Number of subjects: 34
Study 29642115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 34
Study 27032074 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Number of subjects: 690
Study 27032074 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive medication
Number of subjects: 690
Study 27032074 — intervention group
Group type: EXPERIMENTAL
Intervention: All antihypertensive medications
Number of subjects: 690
Study 24008787 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia intervention (scripted verbal informed consent, 3-fold pamphlet, and 3D model presentation)
Number of subjects: 97
Study 24008787 — intervention group
Group type: COMPARATOR
Intervention: Control group (scripted verbal informed consent only)
Number of subjects: 97
Study 24008787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 23085706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided injection
Number of subjects: 47
Study 23085706 — intervention group
Group type: COMPARATOR
Intervention: Manual needle placement
Number of subjects: 47
Study 23085706 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 47
Study 20801856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 124
Study 20801856 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 124
Study 18672254 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 24
Study 18672254 — intervention group
Group type: COMPARATOR
Intervention: Second IVIG infusion (2 g/kg)
Number of subjects: 24
Study 16164708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept plus UVB treatment (6-week and 12-week)
Number of subjects: 60
Study 16164708 — intervention group
Group type: COMPARATOR
Intervention: Alefacept monotherapy
Number of subjects: 60
Study 16164708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (alefacept/UVB)
Number of subjects: 60
Study 12858653 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice daily for up to 28 weeks
Number of subjects: 16
Study 12858653 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice daily
Number of subjects: 16
Study 12858653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10371538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (titrated to approximately 6 mg/kg/d)
Number of subjects: 98
Study 10371538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 98
Study 10371538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 8898424 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2a therapy for 26 weeks
Number of subjects: 97
Study 2060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 0.5 mg
Number of subjects: 31
Study 2060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 1.0 mg
Number of subjects: 31
Study 2060541 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 2.5 mg
Number of subjects: 31
Study 2060541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6295596 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16 (180 mg/m2 on 3 consecutive days at 2 weekly intervals)
Number of subjects: 35
Study 6295596 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 35
Study 6295596 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16
Number of subjects: 35
Study 31859732 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CHAT-R/F
Number of subjects: 120